Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Cardiac Sciences
    • Occluded artery in...

    Occluded artery in STEMI beyond 48 hours -Dr Devkishin Pahlajani

    Written by Anjali Nimesh Nimesh Published On 2018-02-28T15:29:08+05:30  |  Updated On 28 Feb 2018 3:29 PM IST
    Occluded artery in STEMI beyond 48 hours -Dr Devkishin Pahlajani
    Should we perform percutaneous coronary intervention for totally occluded infarct-related artery 3-28 days post myocardial infarction?

    This situation is faced by cardiologists several times in their clinical practice particularly in patients who have failed fibrinolytic therapy or did not reach the PCI capable center or did not receive any fibrinolytic therapy To answer this question Occluded Artery Trial investigators enrolled 2166 patients in a randomized control trial.All of them were stable had evidence of totally occluded infarct-related artery 3-28 days post-MI. They had high-risk features like ejection fraction <50%, proximal occlusion of a major epicardial artery or both


    Primary endpoint was death, MI, or NYHA class IV heart failure PCI was successful in 87% of patients The primary endpoint of death reinfarction or NYHA class IV heart failure occurred in 17.2% of PCI group and 15.6% of medical group (HR 1.16 ,p=0.20).Repeated higher elevation of cardiac Biomarkers within 48 hours occurred significantly more frequently in PCI group (10.0% vs 3.3% p<0.001)


    Individual endpoints of death heart failure were similar in both strategies of treatment Even over the longer median follow up of 5.8 years there was no significant difference in the composite primary end of death, MI between both the arms.


    Individual components of all causes mortality was similar in both groups (22.3% vs 22.9).Reinfarction rates also were similar ( 7.7% vs 7.2%) .However, repeat revascularization was higher in medical arm which did not include revascularisation of infarct-related artery


    Thus the message is clear: There is no advantage of PCI of infarct-related artery over medical treatment in patients 3-28 days post-MI in stable patients Excluded will be patients who experience post-MI angina, cardiac failure Viability with dobutamine stress echo, PET or cardiac MRI should or performed to determine viability Patients with viable muscle are likely to benefit from PCI.


    Dr Devkishin Pahlajani is the Chief of Cardiac Catheterization and Laboratories at Breach Candy Hospital. He is presenting on the topic Occluded artery in STEMI beyond 48 hours at India Live 2018
    cardiac BiomarkersCardiac MRIcutaneous coronary interventionDevkishin PahlajaniDr Devkishin Pahlajanifibrinolytic therapyheart failurePCIrevascularization

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Anjali Nimesh Nimesh
    Anjali Nimesh Nimesh
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok